OS Therapies terminates $18 million at-the-market stock sale agreement

OS Therapies Incorporated disclosed in a Form 8-K that on July 23, 2026, the company delivered written notice to B. Riley Securities, Inc. and JonesTrading Institutional Services LLC terminating the At Market Issuance Sales Agreement dated August 8, 2025, under Sections 13(b) and 14 of that agreement.¹ The termination became effective on July 28, 2026.¹

The agreement had allowed the company to raise capital through periodic stock sales. The Sales Agreement had provided OS Therapies with the ability to offer and sell shares of common stock from time to time up to an aggregate offering price of $18,000,000 through the Sales Agents.¹ On August 25, 2025, the company had filed a prospectus supplement related to the agreement, covering the same $18,000,000 aggregate offering amount.¹

Usage of the facility was limited. At the time of termination, OS Therapies had sold a total of 282,679 shares for aggregate gross proceeds of approximately $530,162, leaving about $17,469,838 unsold under the agreement and prospectus supplement.¹

Following the termination, no further shares of common stock may be offered or sold under the Sales Agreement or the Prospectus Supplement.¹ The company also noted that the exit was clean from a financial standpoint: no termination fees or other payments were due by either party in connection with the termination.¹

The filing was signed by Paul A. Romness, MPH, President and Chief Executive Officer of OS Therapies, dated July 29, 2026. The 8-K does not disclose the company's reasons for ending the agreement or any plans for alternative financing.